Lyell Immunopharma (LYEL) Research & Development (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Research & Development data on file, last reported at $36.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 15.75% year-over-year to $36.6 million; the trailing twelve-month figure through Mar 2026 stood at $151.8 million (down 11.66% YoY), and the FY2025 full-year result was $158.7 million, down 7.53% from the prior year.
• Research & Development retreated to $36.6 million in Q1 2026, from $52.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $52.2 million in Q4 2025 to a low of $28.2 million in Q3 2025.
• A 5-year average of $41.7 million and a median of $43.2 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 97.21% in 2022 and retreated 28.68% in 2025, its largest moves.
• Tracing LYEL's Research & Development over 5 years: stood at $38.0 million in 2022, then increased by 23.57% to $47.0 million in 2023, then increased by 3.56% to $48.7 million in 2024, then gained by 7.26% to $52.2 million in 2025, then declined by 29.88% to $36.6 million in 2026.
• Business Quant data shows LYEL's Research & Development at $36.6 million in Q1 2026, $52.2 million in Q4 2025, and $28.2 million in Q3 2025.